Allogene Therapeutics, Inc. (NASDAQ:ALLO) Insider Timothy L. Moore Sells 14,746 Shares

Allogene Therapeutics, Inc. (NASDAQ:ALLO) insider Timothy L. Moore sold 14,746 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the transaction, the insider now owns 250,713 shares of the company’s stock, valued at $428,719.23. This trade represents a 5.55 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Allogene Therapeutics Stock Performance

ALLO opened at $1.51 on Friday. Allogene Therapeutics, Inc. has a one year low of $1.50 and a one year high of $5.78. The stock has a market cap of $316.60 million, a price-to-earnings ratio of -0.97 and a beta of 0.83. The stock’s 50 day moving average price is $2.01 and its 200-day moving average price is $2.43.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ALLO. William Blair reaffirmed an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. Piper Sandler lowered their price objective on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Allogene Therapeutics in a research report on Friday, November 8th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Allogene Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.73.

Hedge Funds Weigh In On Allogene Therapeutics

Several hedge funds have recently bought and sold shares of ALLO. Geode Capital Management LLC lifted its position in shares of Allogene Therapeutics by 14.4% during the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock worth $9,037,000 after purchasing an additional 407,070 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Allogene Therapeutics by 24.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock valued at $5,944,000 after buying an additional 507,021 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Allogene Therapeutics by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,188,838 shares of the company’s stock valued at $2,532,000 after buying an additional 9,990 shares during the period. Zacks Investment Management bought a new position in Allogene Therapeutics in the 3rd quarter worth about $1,446,000. Finally, The Manufacturers Life Insurance Company grew its stake in Allogene Therapeutics by 1.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company’s stock worth $1,361,000 after acquiring an additional 5,642 shares in the last quarter. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).